Higher Doses of Radiation Therapy Don’t Increase Survival in Prostate Cancer Patients, Phase 3 Trial Finds

Higher Doses of Radiation Therapy Don’t Increase Survival in Prostate Cancer Patients, Phase 3 Trial Finds
While higher doses of radiation therapy in patients with intermediate-risk prostate cancer lower the need for secondary therapies, the approach does not improve overall survival, results from a Phase 3 clinical trial show. The study, “Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer,” was published in JAMA Oncology. Optimizing radiation therapy

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Lawrence Glickman says:

    General statements about phase 3 trials or for that matter any blanket statement like it, are not useful for patients or Doctor choices because each practitioner and patient is unique. This is proven by the government’s varying statistics on the death rates in hospitals around the country which should theoretically be identical. In this case new research has uncovered one of the problems with radiation in general as being related to “Stem cell” type cancer cells that can endure radiation. Various counter measures to these stubborn cells and the accuracy of the new MRI and Computer guided radiation treatments need to looked at specifically and in some hospitals “cure” rates are 90%. Every patient should do specific research on the success rate and protocols of the Doctor they choose.

Leave a Comment

Your email address will not be published. Required fields are marked *